Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO
The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...
Takeda Picks First Woman as CEO of Centuries-Old Drugmaker
Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...
Takeda gains after FY24 guidance raise, CEO transition
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
Christophe Weber, veteran Takeda CEO, to retire next year
Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...
Takeda 9-Month EPS Rises, Revises FY24 Outlook, Julie Kim To Be New CEO
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...
devdiscourse6h
Zydus Takeda's Vashi Plant Celebrates 25 Years of Excellence
Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...
ジャパンタイムズ8h
Takeda picks first female CEO of centuries-old drugmaker
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...
Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed
Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S.
Takeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on Thursday
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...